Cannabis Science, Inc. (OTCBB: CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to provide new photographs of the existing treatment for patient three who has a “worst case” of treatment resistant, Squamous Cell Carcinoma. Cannabis Science has received positive feedback from both the patient and his Oncologist. These photos show the progressive reduction of the tumor masses that has occurred within the months of treatment.
Oncologists have stated that this is the worst case of squamous cell carcinoma, and last week, the patient’s oncologist said the results from the topical cannabis extract are “astonishing.” So instead of needing any surgery this month he is to go back and see the oncologist in June. The patient's wife, who could not even look at her husband’s head months ago, has stated that it looks as if 75% of the tumors masses are gone.
Since Cannabis Science has been working with this patient extensively, Dr. Robert Melamede has provided lots of support and expert scientific advice during the treatment process. Patient three came to Cannabis Science with hope to find a treatment that would work. Due to his extremely severe case of squamous cell carcinoma, his surgeon wanted to remove his scalp and a good portion of his skull. Instead he opted for 135 radiation treatments, but the remaining tumors became radiation and chemotherapy resistant. Dr. Robert Melamede informs that, “Cannabis extracts have the unique ability to holistically improve health. They simultaneously modify numerous biochemical pathways to produces a healthy concerted action.”
You can view these new photos on the Cannabis Science website www.cannabisscience.com and click the button “View Images of 3rd Self-Medicated Patient & His Apparent Success.” You can read more news on this 3rd patient as well on the Cannabis Science website www.cannabisscience.com and click on the breaking news button where you will find all the cancer related and updated patient news.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.Business Wire
Last updated on: 11/04/2012